Spots Global Cancer Trial Database for Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Official Title: A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Study ID: NCT06416007

Conditions

Cancer

Metastatic Cancer

Locally Advanced

Locally Advanced Solid Tumor

Locally Advanced Carcinoma

Interventions

Lattice therapy (LRT)

Study Description

Brief Summary: The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

Detailed Description: This will be a single-institution, single-arm Phase II trial with an anticipated total of 37 patients enrolled. Treatment will consist of 5 fractions of lattice radiation therapy delivered every other day. The primary endpoints will include the efficacy of lattice therapy as evaluated by ORR (CR or PR per RECIST criteria) at 60 days (2 months) post-treatment and safety. Toxicity will be evaluated at day 5 (+/- 2 days), day 15 (+/- 5 days), day 30 (+/- 5 days), and day 60 (+/- 7 days) post-completion of lattice therapy. This study will also include a translational analysis of the impact of lattice therapy on systemic immune responses.